Webbläsaren som du använder stöds inte av denna webbplats. Alla versioner av Internet Explorer stöds inte längre, av oss eller Microsoft (läs mer här: * https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Var god och använd en modern webbläsare för att ta del av denna webbplats, som t.ex. nyaste versioner av Edge, Chrome, Firefox eller Safari osv.

Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies

Författare

  • S. M. Gapstur
  • A. V. Patel
  • E. Banks
  • L. Dal Maso
  • R. Talamini
  • A. Chetrit
  • G. Hirsh-Yechezkel
  • F. Lubin
  • S. Sadetzki
  • V. Beral
  • D. Bull
  • B. Cairns
  • B. Crossley
  • K. Gaitskell
  • A. Goodill
  • J. Green
  • C. Hermon
  • T. Key
  • K. Moser
  • G. Reeves
  • F. Sitas
  • R. Collins
  • R. Peto
  • C. A. Gonzalez
  • N. Lee
  • P. Marchbanks
  • H. W. Ory
  • H. B. Peterson
  • P. A. Wingo
  • N. Martin
  • S. Silpisornkosol
  • C. Theetranont
  • B. Boosiri
  • S. Chutivongse
  • P. Jimakorn
  • P. Virutamasen
  • C. Wongsrichanalai
  • M. T. Goodman
  • O. Lidegaard
  • S. K. Kjaer
  • L. S. Morch
  • S. K. Kjaer
  • A. Tjonneland
  • T. Byers
  • T. Rohan
  • B. Mosgaard
  • M. Vessey
  • D. Yeates
  • J. L. Freudenheim
  • L. J. Titus
  • J. Chang-Claude
  • R. Kaaks
  • K. E. Anderson
  • D. Lazovich
  • K. Robien
  • J. Hampton
  • P. A. Newcomb
  • M. A. Rossing
  • D. B. Thomas
  • N. S. Weiss
  • E. Lokkegaard
  • E. Riboli
  • F. Clavel-Chapelon
  • D. Cramer
  • S. E. Hankinson
  • R. M. Tamimi
  • S. S. Tworoger
  • S. Franceschi
  • C. La Vecchia
  • E. Negri
  • H. O. Adami
  • C. Magnusson
  • T. Riman
  • E. Weiderpass
  • A. Wolk
  • L. J. Schouten
  • P. A. van den Brandt
  • N. Chantarakul
  • S. Koetsawang
  • D. Rachawat
  • D. Palli
  • A. Black
  • L. A. Brinton
  • D. M. Freedman
  • P. Hartge
  • A. W. Hsing
  • J. V. Lacey Jnr
  • J. Lissowska
  • R. N. Hoover
  • C. Schairer
  • C. Babb
  • M. Urban
  • S. Graff-Iversen
  • R. Selmer
  • C. J. Bain
  • A. C. Green
  • D. M. Purdie
  • V. Siskind
  • P. M. Webb
  • K. Moysich
  • S. E. McCann
  • P. Hannaford
  • C. Kay
  • C. W. Binns
  • A. H. Lee
  • M. Zhang
  • R. B. Ness
  • P. Nasca
  • P. F. Coogan
  • J. R. Palmer
  • L. Rosenberg
  • A. Whittemore
  • K. Katsouyanni
  • A. Trichopoulou
  • D. Trichopoulos
  • A. Tzonou
  • A. Dabancens
  • L. Martinez
  • R. Molina
  • O. Salas
  • G. Lurie
  • M. E. Carney
  • L. R. Wilkens
  • Linda Werner Hartman
  • Jonas Manjer
  • Håkan Olsson
  • M. Kumle
  • J. A. Grisso
  • M. Morgan
  • J. E. Wheeler
  • R. P. Edwards
  • J. L. Kelley
  • F. Modugno
  • N. C. Onland-Moret
  • P. H. M. Peeters
  • J. Casagrande
  • M. C. Pike
  • A. H. Wu
  • K. Canfell
  • A. B. Miller
  • I. T. Gram
  • E. Lund
  • L. McGowan
  • X. O. Shu
  • W. Zheng
  • T. M. M. Farley
  • S. Holck
  • O. Meirik
  • H. A. Risch

Summary, in English

Background Half the epidemiological studies with information about menopausal hormone therapy and ovarian cancer risk remain unpublished, and some retrospective studies could have been biased by selective participation or recall. We aimed to assess with minimal bias the effects of hormone therapy on ovarian cancer risk. Methods Individual participant datasets from 52 epidemiological studies were analysed centrally. The principal analyses involved the prospective studies (with last hormone therapy use extrapolated forwards for up to 4 years). Sensitivity analyses included the retrospective studies. Adjusted Poisson regressions yielded relative risks (RRs) versus never-use. Findings During prospective follow-up, 12 110 postmenopausal women, 55% (6601) of whom had used hormone therapy, developed ovarian cancer. Among women last recorded as current users, risk was increased even with <5 years of use (RR 1.43, 95% CI 1.31-1.56; p<0.0001). Combining current-or-recent use (any duration, but stopped <5 years before diagnosis) resulted in an RR of 1.37 (95% CI 1.29-1.46; p<0.0001); this risk was similar in European and American prospective studies and for oestrogen-only and oestrogen-progestagen preparations, but differed across the four main tumour types (heterogeneity p<0.0001), being definitely increased only for the two most common types, serous (RR 1.53, 95% CI 1.40-1.66; p<0.0001) and endometrioid (1.42, 1.20-1.67; p<0.0001). Risk declined the longer ago use had ceased, although about 10 years after stopping long-duration hormone therapy use there was still an excess of serous or endometrioid tumours (RR 1.25, 95% CI 1.07-1.46, p=0.005). Interpretation The increased risk may well be largely or wholly causal; if it is, women who use hormone therapy for 5 years from around age 50 years have about one extra ovarian cancer per 1000 users and, if its prognosis is typical, about one extra ovarian cancer death per 1700 users.

Avdelning/ar

Publiceringsår

2015

Språk

Engelska

Sidor

1835-1842

Publikation/Tidskrift/Serie

The Lancet

Volym

385

Issue

9980

Dokumenttyp

Artikel i tidskrift

Förlag

Elsevier

Ämne

  • Cancer and Oncology

Status

Published

Forskningsgrupp

  • Surgery

ISBN/ISSN/Övrigt

  • ISSN: 1474-547X